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Pilot Study of Delayed ICOS/ICOS-L BlockadeWith
aCD40 to Modulate Pathogenic Alloimmunity in a
Primate Cardiac Allograft Model
Natalie A. O’Neill, MD,1 Tianshu Zhang, MD, PhD,1 Gheorghe Braileanu, PhD,1 Xiangfei Cheng, MD, PhD,1
Alena Hershfeld, MS,1 Wenji Sun, MD, PhD,1 Keith A. Reimann, PhD,2 Sia Dahi, MD,1 Natalia Kubicki, MD,1
Wessam Hassanein, MD,1 Christopher Laird, MD,1 Arielle Cimeno, MD,1 Agnes M. Azimzadeh, PhD,1
and Richard N. Pierson, MD1,3
Background. Inducible costimulator (ICOS) is rapidly upregulatedwith T-cell stimulation andmay represent an escape pathway
for T-cell costimulation in the setting of CD40/CD154 costimulation blockade. Induction treatment exhibited no efficacy in a primate
renal allograft model, but rodent transplant models suggest that the addition of delayed ICOS/ICOS-L blockade may prolong al-
lograft survival and prevent chronic rejection. Here, we ask whether ICOS-Ig treatment, timed to anticipate ICOSupregulation, pro-
longs NHP cardiac allograft survival or attenuates pathogenic alloimmunity.Methods.Cynomolgus monkey heterotopic cardiac
allograft recipients were treated with αCD40 (2C10R4, d0-90) either alone or with the addition of delayed ICOS-Ig (d63-110).
Results.Median allograft survival was similar between ICOS-Ig + αCD40 (120 days, 120-125 days) and αCD40 (124 days,
89-178 days) treated animals, and delayed ICOS-Ig treatment did not prevent allograft rejection in animals with complete
CD40 receptor coverage. Although CD4+ TEM cells were decreased in peripheral blood (115 ± 24) and mLNs (49 ± 1.9%) during
ICOS-Ig treatment compared with monotherapy (214 ± 27%, P = 0.01; 72 ± 9.9%, P = 0.01, respectively), acute and chronic re-
jection scores and kinetics of alloAb elaboration were similar between groups. Conclusions. Delayed ICOS-Ig treatment with
the reagent tested is probably ineffective in modulating pathogenic primate alloimmunity in this model.
(Transplantation Direct 2018;4: e344; doi: 10.1097/TXD.0000000000000761. Published online 24 January, 2018.)
Costimulation pathway blockade with belatacept is anestablished alternative therapeutic strategy in clinical
transplantation, allowing safe reduction in exposure to neph-
rotoxic calcineurin inhibitors. Blockade of the CD40/CD154
pathway in preclinical models via αCD40 treatment has
demonstrated prolonged allograft survival and delayed pro-
duction of donor specific antibodies in nonhuman primate
(NHP) renal,1 islet cell,2,3 and cardiac4 models. However,
αCD40 (or αCD1544-7) monotherapy has been associated
with chronic rejection, and a minority of allografts even reject
during treatment, identifying existence of rejectionmechanisms
that are resistant toCD40/CD154-directed costimulation path-
way blockade.
Based on prior work by us and others in preclinical models
and in man, we hypothesized that immune injury associated
with CD40/CD154-directed costimulation blockade is medi-
ated by one of several known alternative costimulation path-
ways. One pathway of particular interest is the inducible
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costimulator (ICOS)/ICOS-ligand (ICOS-L) pathway. ICOS
is rapidly induced after T-cell receptor cross-linking. ICOS
is expressed on activated CD4+ and CD8+ Tcells and effector
CD4+ T follicular helper (Tfh) cells within the germinal cen-
ter,8 enhances T-cell responses to foreign antigens, and ICOS
expression is increased in acutely9-11 and chronically5,10,12
rejected allografts. One benefit of ICOS blockade over other
costimulation targets may be the pathway’s relative specific-
ity for upregulation on activated, pathogenic T cells.
In support of this paradigm, ICOS-Ig monotherapy moder-
ately prolonged allograft survival in mice,13,14 and the combi-
nation blockade of the CD40/CD154 pathway with ICOS/
ICOS-L pathway demonstrated significantly prolonged sur-
vival in rodent transplant models.10,12,15,16 Murine transplant
and autoimmune models have further demonstrated benefit
with delayed treatment of ICOS-Ig on both allograft survival,
disease pathology, and suppression of CD4+ and CD8+ effec-
tor memory cell populations.14,17-20 In contrast, the first
NHP preclinical trial of ICOS-Ig, administered for one month
(until day 28),21 in combination with ongoing CD28/B7
blockade, did not prolong kidney allograft survival. Based
on our observation that ICOS expression generally becomes
detectable in cynomolgus monkey cardiac allografts about
2 months after transplant, here we evaluate whether delayed
ICOS-Ig treatment, timed to anticipate ICOS upregulation in
the graft, prolongs allograft survival or attenuates pathogenic
alloimmunity in that model.
METHODS
Animal Model
Captive-bred cynomolgus monkeys (Macaca fascicularis)
of Chinese and Indonesian origin were used. Males weighing
5.0 to 9.5 kg received ABO blood type-compatible hearts
from donors that were selected based on stimulation index
>5 in mixed lymphocyte reaction to confirmmajor histocom-
patibility complex (MHC) class II mismatch. MHC class I
mismatch was confirmed retrospectively by detection of anti-
donor class I (T cell) alloantibodies, or in exceptional cases
where antibody was not detected, by genomic DNA Illumina
sequencing.4 All protocols were approved by the Institu-
tional Animal Care and Use Committee at the University of
Maryland School of Medicine and were conducted in com-
pliance with the National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals.
Surgical Procedures and Allograft Monitoring
Heterotopic intra-abdominal cardiac transplantation was
performed as described previously.22 Cardiac biopsies were
obtained by protocol on postoperative days (d) 14, 42, 90,
and 150; biopsies were occasionally omitted or delayed due
to recipient anemia or weight loss. Mesenteric lymph nodes
(mLNs) were usually sampled at the time of biopsy.
Core temperature and graft heart rate, systolic blood pres-
sure, and diastolic blood pressure were assessed at least once
daily using intra-abdominal telemetry (D70-PCTP or L11,
Data Sciences International, St. Paul, MN) until time of graft
explant for failure. Allograft failure was defined by one or
more of the following criteria for 2 consecutive days: decline
in heart rate greater than 20% below baseline or less than
120 beats per minute, pulse pressure less than 30 mm Hg, or
nonpalpable graft contraction.
Immunosuppression
All animals (n = 9) received αCD40 treatment using
2C10R4, a mouse-rhesus IgG4κ anti-CD40 antibody,2 intra-
venously (IV) at 30 mg/kg on d0, d3, d7, and d14; 10 mg/kg
on d21, d28, d35, and d42; and 20 mg/kg on d56 and d84
(total 200 mg/kg). Six animals received αCD40 alone, as pre-
viously reported,4 and 3 animals additionally received ICOS-
Ig, a rhesus recombinant Ig-fusion protein, in combination
with αCD40 beginning on d63 (Figure 1). Both 2C10R4
and ICOS-Ig were obtained from NIH Nonhuman Primate
Reagent Resource (Boston, MA).
The ICOS-Ig protein, comprising the 141 extracellular amino
acids of rhesus ICOS (Genbank accession NM_001266989.1)
and the hinge, CH2 and CH3 domains of rhesus IgG1, was
expressed using theGPExÒ technology (Catalent Pharma Solu-
tions, Madison, WI). Briefly, DNA encoding the Ig fusion
protein was inserted into an expression vector and Chinese
hamster ovary (CHO) cells were transduced with this vector
using replication incompetent retrovirus. A pool of transduced
CHO cells was grown in serum free medium and ICOS-Ig pu-
rified using conventional protein A affinity chromatography.
The final product was formulated in PBS, pH 7.0.
ICOS-Ig dosing was progressively adjusted in the 3 ani-
mals receiving combination treatment based on interval graft
fates and in response to pharmacokinetic data showing low
trough levels (Figure 2). The first animal, DV8T, received
5 mg/kg weekly from d63 to d90 (25 mg/kg total). The
second animal, DM4XX, received 10 mg/kg on d63, 70;
5 mg/kg on d77, d84, and d90; and 10 mg/kg on d98 and
d105 (55 mg/kg). The third animal, DW4P, received 5 mg/kg
twice weekly from d63 until d109 (70 mg/kg).
Routine monitoring for CMVwas not performed, and an-
tiviral medications were not used.
Drug Trough Levels and CD40 Receptor Coverage
Serum trough αCD40 levels were checked retrospectively
by enzyme-linked immunosorbent assay and peripheral
blood CD40 receptor saturation was measured by flow cy-
tometry, as described previously.4
FIGURE 1. αCD40 and ICOS-Ig dosing schematic. Heterotopic car-
diac allograft transplantation in NHP was performed on d0. All ani-
mals received αCD40 from d0 to d84 (total of 200 mg/kg). ICOS-Ig
(n = 3) was given in a delayed fashion from d63 to d109, and dosing
was progressively escalated in each animal. Solid black arrows indi-
cate doses that each animal within the treatment group received.
Dotted black arrows indicate additional ICOS-IG doses given during
the dose escalation.
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Serum peak and trough ICOS-Ig levels were also ana-
lyzed retrospectively by enzyme-linked immunosorbent as-
say. Maxisorp 96- well plates were coated with ICOS-L
(ICOSLG Sino Biological Inc, Beijing, China) at 1 μg/mL in
PBS and were incubated at 4°C overnight. Plates were washed
with PBS-Tween 20 0.05% (Sigma-Aldrich, St. Louis, MO),
blocked with PBS containing 3% bovine serum albumin
(Sigma-Aldrich), and serum samples were incubated followed
by goat anti-human IgG secondary antibody and HRP
(Jackson ImmunoResearch Laboratories, Inc. West Grove,
PA). Due to its inducible nature, reliable flow cytometry
methods to detect ICOS receptor coverage have not been
developed.
Histological Grading of Acute and Chronic Rejection
Biopsy and explant cardiac tissue specimenswere fixedwith
10% formalin, processed for paraffin embedding, and stained
with hematoxylin and eosin, as described previously.23 Acute
cellular myocardial infiltration was graded using the 2005
International Society for Heart and Lung Transplantation
(ISHLT) revised criteria for cardiac allograft rejection.24 Car-
diac allograft vasculopathy (CAV) severity with hematoxylin
and eosin staining was scored by 3 independent evaluators
(N.A.O. or L.B., T.Z., and R.N.P.), who were blinded with
respect to treatment group.23
Lymphocyte Detection and Memory
T- and B-Cell Analysis
Routine blood collection was performed per protocol
to monitor cell blood counts, B and T lymphocyte subsets,
blood chemistry, and antidonor alloantibody (alloAb) pro-
duction, as previously described.4
Peripheral blood was stained for cell surface markers CD3
(clone SP34-2), CD4 PerCP (clone L200), CD8 APC (clone
SK1), CD28 (clone 28.2), CD62L (clone SK11), CD45RA
(clone 5H9), and CD95 (clone DX2). Samples were collected
using FACSCalibur cytometer (BD Biosciences), and data
analysis was conducted using FlowJo 10.1r5 (Treestar,
Ashland, OR) software.
Lymph nodeswere blockedwith pure human IgG (Jackson
ImmunoResearch), stained with e780 fixable viability dye
(eBioscience), and then stained with the T-cell surface markers
described above and CD20 (clone L27), CD27 (clone
MT271), CD38 (clone OKT10), IgD (goatαhuman; Southern
Biotech, Birmingham, AL), and IgM (W6/32, NIHNonhuman
Primate Reagent Resource). CD3+ T memory cell phenotypes
were defined as naive (TN) CD45RA
+CD95−CD28+CD62L+,
central memory (TCM) CD45RA
−CD95+CD28+CD62L+, or
effector memory (TEM) CD45RA
+/−CD95+/−CD28−CD62L−.25
CD20
+
B memory cell phenotypes were defined as naive
IgD+CD27−CD38+IgMintermediate, isotype-switched B memory
cell CD27+IgD−, and nonswitched Bmemory CD27+IgD+.26,27
alloAb Detection
alloAb was measured retrospectively by flow cytometry
using archived frozen donor splenocytes and recipient sera.
AlloAb elaboration was defined as consistently detected IgM-
positive or IgG-positive donor CD3+CD20− T cells greater
than 10% relative to donor serum before transplant, as de-
scribed previously.23
Statistical Analysis
Survival analysis was performed by the Kaplan-Meier
method and compared using the log-rank test. Continuous
variables were expressed as the mean ± standard error of the
mean (SEM) or median and interquartile ranges, and these
were compared using either the 2-tailedMann-WhitneyU test
to compare 2 groups or 1-way analysis of variance on ranks
for comparing 3 or more groups. Nominal variables were
compared using a contingency table and the Fisher exact test.
P values less than 0.05were considered statistically significant.
All statistical analyseswere performed on a personal computer
with GraphPad InStat (version 3.01; GraphPad Software,
San Diego, CA).
RESULTS
ICOS-Ig Dose Escalation
For the αCD40 + ICOS-Ig–treated animals, serum ICOS-
Ig levels were analyzed retrospectively to determine serum
drug levels before and 30 minutes after ICOS-Ig dosing. Al-
though peak levels (mean ± SEM 78 ± 11 μg/mL) achieved
FIGURE 2. Serum ICOS-Ig peak and trough levels. ICOS-Ig treatment was started on d63 in each animal. Solid arrows represent ICOS-Ig
doses corresponding to either 5 mg/kg or 10 mg/kg. ICOS-Ig treatment was progressively escalated in each animal from a total of 25 mg/kg
(DV8T) to 55mg/kg (DM4XX) to 70mg/kg (DW4P). Trough levels were drawn before ICOS-Ig administration intravenously. Peak serum levels were
sampled approximately 30 minutes after ICOS-Ig administration. Dotted lines represent time points when either a peak or trough level was not
drawn between data points. Serum trough levels (DV8T: 0.9 ± 0.4, DM4XX: 0.3 ± 0.03, DW4P: 0.9 ± 0.1; one way ANOVA rank P = 0.03) and
serum peak levels (DV8T: 78 ± 11, DM4XX: 86 ± 19, DW4P: 123 ± 10; P = 0.08) increased with dose escalation. ANOVA, analysis of variance.
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our expected target (>50 μg/mL), ICOS-Ig serum trough levels
in the first animal, DV8T (0.9 ± 0.4 μg/mL) were lower than
anticipated. Given this observation, ICOS-Ig dosing was esca-
lated for subsequent animals (Figure 2). Although peak levels
increased proportionate to the administered dose after each
infusion, trough levels remained lower than expected (DW4P:
0.9 ± 0.1 μg/mL; P = 0.03). These results suggest that the
half-life of this molecule was shorter than expected.
Allograft Survival
Median survival time (MST) of the combination αCD40 +
ICOS-Ig–treated animals (n = 3, MST 120 days; range,
120-125) was similar to αCD40 monotherapy (n = 6, 124,
89-178; P = 0.6, Figure 3). Specifically, ICOS-Ig treatment
did not have a measureable effect on allograft survival. Two
animals in the 2C10R4 treatment group (FB9N and DV36)
had functional, beating allografts removed for health reasons
(Table 1), as reported previously.4
Before αCD40 re-dosing, CD40 receptor coverage was reg-
ularly assessed. CD40 receptor coverage was nearly 100% for
at least 35 days after the final αCD40 treatment, and similar
between αCD40 alone (98.8 ± 0.8% on d118) and
αCD40 + ICOS-Ig (99.0 ± 1.0% on d118, P = 0.8; Figure 4).
One of 4 evaluable animals in the αCD40-treatment group
(FA53) and 2 of 3 animals in the combination group (DM4XX
and DW4P) exhibited graft rejection despite 100% recep-
tor coverage (Table 1). These data demonstrate existence
of graft injury mechanisms escaping control by CD40-
directed treatment, alone or with ICOS-Ig, despite persistent,
prevalent CD40 receptor coverage.
Acute and Chronic Rejection Acute Cellular Infiltration
Protocol biopsies and explanted cardiac allografts were
evaluated for evidence of acute and chronic rejection, and
time points were grouped by αCD40 alone (d0-60 for both
groups), during treatment with ICOS-Ig (d61-110), or after
ICOS-Ig treatment (d111-180). Acute cellular infiltration
graded by ISHLTscore24 was similar between αCD40mono-
therapy and αCD40 + ICOS-Ig–treated animals at each time
point (Figure 5A). Chronic allograft vasculopathy (CAV)
severity was also similar at each time point between the 2
groups (Figure 5B). These data demonstrate participation
of both acute (cellular) and chronic (as CAV) rejection
mechanisms that escape control by CD40-directed treatment
and are not modulated by ICOS-Ig as administered.
alloAb Production
Because others have shown that αICOS inhibits alloAb
isotype switching,16 we evaluated IgM and IgG alloAb pro-
duction after transplantation. IgM alloAb elaboration from
d0 to d60 was significantly higher in the αCD40 + ICOS-Ig
(7 of 22 time points with IgMalloAb >10%;P = 0.0004) than
the αCD40 monotherapy treatment group (0 of 38) because
one animal (DV8T)within theαCD40 + ICOS-Ig group devel-
oped IgM antidonor alloAb on d7 (d7-118 mean ± SEM:
18 ± 1.4%; Figure 6).
During ICOS treatment (d61-110) and after ICOS treat-
ment (d111-180), IgM and IgG alloAb detection was similar
between the 2 groups and elaboration occurred just prior or
at the time of allograft rejection. Together, these data demon-
strate participation of humoral (as anti-donor alloantibody)
rejection mechanisms that escape control by CD40-directed
FIGURE 3. Kaplan-Meir allograft survival curve. Graft rejection was
defined by one or more of the following criteria for 2 consecutive
days: decline in heart rate >20% below baseline or <120 beats per
minute, pulse pressure <30 mm Hg, or nonpalpable graft contrac-
tion. MST is similar between the 2 treatment groups. (+) represent al-
lografts removed without evidence of rejection, and are censored
from survival analyses. αCD40 (d0-d84) and ICOS-Ig (d63-d109)
treatment time periods are denoted with arrows. αCD40 monother-
apy control group was previously reported.4
TABLE 1.
Individual animal survival and receptor coverage at time of
allograft explant
Treatment groups Animal ID Allograft survival (d) Receptor coverage (%)a
αCD40 FB9N >25 100
DV36 >69 100
FC9J 89 88
FA53 117 100
DV2R 130 48
FB6E 178 0
αCD40 + ICOS-Ig DW4P 120 100
DM4XX 120 99
DV8T 125 17
Animals with adequate CD40 receptor coverage at the time of explant (FA53, DW4P, DM4XX) may
represent costimulation blockade resistant rejection. Shaded boxes represent animals with functional,
beating allografts removed for other health reasons.
a CD40 receptor coverage at the time of allograft explant.
FIGURE 4. Mean peripheral blood CD40 receptor coverage (%)
detected by flow cytometry. SEM is demonstrated in error bars.
Solid arrows represent αCD40 dosing. Receptor coverage was nearly
100% through d118, after which point coverage becomes somewhat
variable across animals.
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treatment and suggest that the addition of delayed ICOS-Ig
treatment, as administered, was unable to prevent alloAb
isotype switching.
mLN Memory B-Cell Prevalence
Given the failure of ICOS-Ig treatment to prevent alloAb
isotype switch, we evaluated the prevalence of memory B cells
inmLNafter ICOS-Ig treatment. The proportion of naive B cells
detected by flow cytometry within lymph node was similar
between the 2 groups (Figure 7 and SDC Figure S1,
http://links.lww.com/TXD/A57). The proportion of isotype-
switch memory B cells significantly increased in the
αCD40 + ICOS-Ig–treated animals in mLN from d90 and
d120 (42 ± 9.1%) compared with αCD40-treated animals
(5.8 ± 1.1%; P = 0.04), and, reciprocally, nonisotype
switched memory B cells trended down in the combination
group (2.0 ± 0.6% vs. 8.0 ± 2.3%; P = 0.07). Together with
the alloAb data, delayed ICOS-Ig treatment did not prevent
development of isotype switched memory B cells within the
regional lymph node and subsequent humoral rejection.
Memory T Cell Kinetics in Blood and Lymph Nodes
Several murine models have demonstrated a decrease in
TEM cells with disruption of the ICOS/ICOS-L pathway,
14,28
which prompted us to study the kinetics of TN, TCM, and
TEM cells in peripheral blood. From d70 to d130, time points
during and after ICOS-Ig treatment, CD4+ TEM cells were
significantly lower in the αCD40 + ICOS-Ig animals
(115 ± 24 cells/μL blood) compared with αCD40–treated an-
imals (214 ± 27; P = 0.01), and a similar trend was observed
in the CD8+ TEM cells (527 ± 60 vs. 736 ± 120; Figure 8 and
SDC Figure S2, http://links.lww.com/TXD/A58). CD8+ TCM
cells were significantly higher in the αCD40 + ICOS-Ig group
(102 ± 8) than in αCD40 monotherapy (65 ± 5; P = 0.0004);
however, this cell population was also elevated from d0 to
d65 in the combination group (83 ± 7) than in the αCD40
monotherapy group (50 ± 5; P = 0.0001).
Similarly, CD4+ TEM cell comprised a significantly lower
proportion of CD4+ cells inmLN in associationwith ongoing
ICOS-Ig treatment (49 ± 1.9% at d90 and d120) compared
to αCD40 monotherapy (72 ± 9.9%; P = 0.01, Figure 9
and SDC Figure S3, http://links.lww.com/TXD/A59). This
relative decrease in the mLN CD4+ TEM cell population was
accompanied by a relative increase in CD4+ TN proportion
(45 ± 1.4 vs. 21 ± 6.3%; P = 0.002), whereas CD4+ TCM pro-
portions remained stable and similar between the 2 groups.
These results suggest that ICOS-Ig treatment significantly
skews the CD4+ TEM cell trafficking in blood and secondary
lymphatic compartments, as expected based on rodent studies.
DISCUSSION
ICOS was discovered as a CD28-homologous structure
expressed on activated T cells. ICOS is absent on naive T cells
but is rapidly upregulated on both CD4+ and CD8+ T cells af-
ter Tcell receptor cross-linking. CD28 ligation augments ICOS
expression, but is not necessarily required.29,30 Its ligand,
ICOS-L (B7RP-1, B7h, GL50),9,31 is constitutively expressed
on B cells and immature dendritic cells (DC). ICOS-L expres-
sion is induced on monocytes, macrophages, and other non-
hematopoietic cells like fibroblasts and endothelial cells after
inflammatory stimuli.12,32,33
The ICOS/ICOS-L pathway appears to play a nonredun-
dant role in T-cell costimulation, proliferation, and expan-
sion.34,35 ICOS enhances T-cell response to an antigen by
increasing cytokines such as IL-5, TNF-α, IFN-γ,12,29,31,36
and Th2 cytokines IL-429,37 and IL-10.9,12 ICOS also appears
to play a role in chemokine receptors CCR1, CCR2, CCR5,
CXCR3, CXCR4, and CXCR5 expression.12,38,39 Together,
these cytokines and chemokines are induced upon T-cell acti-
vation and play a role in allograft rejection. These consider-
ations justify efforts to explore blockade of the ICOS/ICOS-L
pathway to prevent alloimmune injury in transplantation.
Early ICOS blockade (αICOS or αICOS-L) in murine car-
diac13-15 or hepatic40 transplant models found that early treat-
ment, initiating on d0, was associated with a modest, though
significant, increase in allograft survival compared to untreated
controls; however, survival was similar between untreated con-
trols and ICOS-Ig–treated NHP.21 In autoimmune mouse
models of EAE, asthma, and diabetes, early αICOS treatment
during the antigen priming phase was found to increase the se-
verity of disease, cell infiltration, and damaging cytokine ex-
pression.17,18,41 When αICOS treatment was delayed and
given after T-cell activation, clinical disease was abrogated at
the clinical and cellular level.17,18 Delayed blockade of the
ICOS/ICOS-L pathway in mouse cardiac models significantly
prolonged allograft survival and decreased cellular infiltration,
FIGURE 5. Acute and chronic rejection histology grading of protocol
biopsies and explanted allografts shown as box and whisker plots.
Fromd0 to d60, both experimental groups received onlyαCD40. From
d61 to d100, the combination group (black) received αCD40 + ICOS-
Ig. A, Median ISHLTacute cellular infiltration score was similar between
the 2 groups. B, Median CAV, a measure of chronic rejection, severity
scores were also similar between both groups. Outlier data points are
shown as dots.
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vasculopathy severity, and IgG alloAb production.14,19,20
Given these encouraging results, we chose to evaluate delayed
ICOS-Ig treatment in a MHC mismatched cardiac allograft
NHP model.
Efficacy appears to be most consistent when the ICOS/
ICOS-L pathway is targeted in conjunction with CD40/
154 pathway blockade10,12,15 whereas heterogeneous re-
sults,10,13,20,21,42 including deleterious effects with shorter
graft survival,14,43 have been reported when ICOS/ICOS-L
targeting is combined with αCD28/B7 blockade. These con-
siderations informed our current experimental design, and
we chose to combine delayed ICOS-Ig with αCD40, rather
than calcineurin inhibition or αCD154, based on several con-
siderations. In our NHP model, αCD40 consistently prolongs
allograft survival as a monotherapy during treatment, with re-
producible detection of ICOS at around 60 days, followed by
progressive chronic rejection leading to graft loss.4 In contrast,
either 5C8H1 or cyclosporine A are associatedwith failure of
some grafts during treatment4,5,23 and inconsistent kinetics
of first ICOS detection by PCR and IHC (AA, unpublished
observations). However, our resulting pilot data suggest that
delayed ICOS-Ig, as applied here, does not significantly at-
tenuate cardiac allograft rejection mechanisms associated
with αCD40 costimulation blockade.
T cells expressing ICOS are phenotypically resting or TEM
cells,9,28,31,39 and these ICOS+ T memory cells can undergo
rapid expansion independent of CD28/B7 or CD40/CD154
ligation.44 As predicted from ICOS-deficient human and
mice,28,39 in this study ICOS-Ig treatment demonstrated a de-
crease of CD4+ TEM cells in peripheral blood and mLNs dur-
ing treatment. In contrast to rodent studies,14,15 the decrease
of TEM cells in our study did not affect allograft survival or
acute or chronic rejection after transplantation, which may
be due to intact cytotoxic CD8+ T cell responses of the
FIGURE 6. Anti-donor alloantibody production after transplantation. The last data point for each animal represents the time of allograft explant.
IgG alloAb elaboration was attenuated in both groups until the time of allograft rejection.
FIGURE 7. mLN B memory cell phenotype by flow cytometry with αCD40 alone (grey) or αCD40 + ICOS-Ig (black). Lymph nodes from protocol
biopsies ond90andd120 represent samples after delayed ICOS-Ig treatment. NaiveB cellswere defined asCD20+IgD+CD27−CD38+IgMintermediate,
nonswitched (NS) BmemoryCD20+CD27+IgD+, and isotype-switched (IS) Bmemory cell CD20+CD27+IgD−. After ICOS-Ig treatment, ISBmemory
proportion significantly increased (42 ± 9.1%), NSBmemory trended downward (2.0 ± 0.6%), and naive B cells were similar (5.7 ± 2.4%) compared
with αCD40 monotherapy (5.8 ± 1.1%, 8.0 ± 2.3%, 23 ± 17%, respectively). Light grey lines represent the mean. ** P = 0.04.
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remaining TEM cell,
10 CD8+ICOS+ TEM cells that divide
within the allograft after crossing the endothelial barrier,45
or the loss of inhibitory effector functions of regulatory Tcells,
which is dependent on ICOS/ICOS-L signaling.18,28,41 Our re-
sults do not provide compelling evidence regarding any of
these nonexclusive hypotheses.
ICOS expression within lymph nodes is predominately on
Tfh cells within the germinal center where T cells induce the
terminal differentiation patterns of B cells into plasma ormem-
ory cells.8,9,46,47 Although we did see a similar effect of ICOS-
Ig on TEM cell phenotype in mLNs as has been described in
mice, we did not observe a difference in IgM alloAb develop-
ment or IgG alloAb class switch between αCD40 and combi-
nation ICOS-Ig + αCD40–treated NHP. Failure to modulate
class switching was unexpected, as others have demonstrated
limited alloAb isotype switching with disruption of ICOS/
ICOS-L.16,36,37 Furthermore, ICOS-deficient mice and human
have reduced Tfh (CD4+CXCR5+) cells39 suggesting B mem-
ory cells may be affected by ICOS; however, we found an in-
creased proportion of isotype switch B memory cells after
ICOS-Ig treatment within regional lymph nodes. The contin-
ued persistence of B memory cells and ability to produce
alloAb likely contributed to the ineffectiveness of ICOS-Ig
in our study, although we cannot exclude the possibility that
either the dose or pharmacologic characteristics of our mole-
cule were inadequate to efficiently block the ICOS/ICOS-L
pathway in vivo.48
The lack of synergistic effects with delayed ICOS-Ig in this
NHP study compared with previous rodent studies may be
due to several other factors. The reagent target itself, ICOS-
Ig, combines with its ligand on APC, preventing ligation of
ICOS on T cells, whereas αICOS binds the ICOS receptor on
T cells, potentially leading directly to effects on the ICOS-
expressing T-cell population. Although an ICOS-Ig for hu-
man use is not currently available,49 2 different αICOS
monoclonal antibodies, MEDI-570 (ClinicalTrials.gov Iden-
tifier: NCT01127321 and NCT02520791) and AMG 557
(ClinicalTrials.gov Identifier: MCT02334306),50 are in phase
1 and phase 2, respectively, clinical trials for SLE, Sjögren’s
syndrome, and refractory T-cell lymphoma. Alternatively, the
ICOS-Ig dose may not have been sufficiently intensive to satu-
rate the pervasive constitutive expression of ICOS-L on APC
and nonhematopoietic cells. This interpretation is supported
by the dose escalation that was required15 to demonstrate
modest survival improvement reported in a similar model,42
and our inability to achieve increased ICOS-Ig trough levels
despite dose escalation. Finally, the most sensitive method
to detect ICOS expression remains unclear, and, therefore,
the optimal timing of delayed ICOS-Ig treatment may not
have been achieved in this study.
In summary, this pilot study of delayed ICOS-Ig treatment
in combination with αCD40 failed to prolong primate car-
diac allograft survival, or to significantly modulate acute re-
jection, chronic rejection, or alloAb elaboration, despite an
FIGURE 8. Peripheral blood T memory cell kinetics after transplantation. CD3+CD4+ and CD8+ Tcells were identified using flow cytometry. T
memory cell phenotypes were characterized as naive (N: CD45RA+CD62L+CD28+ or CD95−CD62L+CD28+), TCM (CD45RA
−CD62L+CD28+
or CD95+CD62L+CD28+), or TEM cell (CD45RA
+/−CD62L−CD28− or CD95+/−CD62L−CD28−). During ICOS-Ig treatment (black, n = 3), CD4+
TEM cells significantly decreased compared to αCD40 monotherapy (grey, n = 6). No significant difference was seen in the CD8
+ TEM pheno-
type. SEM is demonstrated in error bars. *P = 0.01, **P = 0.0004.
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observed decrease in TEM cell in blood and lymph nodes dur-
ing treatment. Together with the pilot study results from Lo
et al. showing similar allograft results with early ICOS-Ig
treatment with CTLA-4Ig, we provisionally conclude that
ICOS-Ig, as tested, is ineffective in preventing costimulation
blockade resistant rejection. Although a reagentwith improved
pharmacodynamics or demonstrated efficacy in anothermodel
would arguably justify reconsideration in transplantation, our
future study regarding mechanisms to better protect grafts in
recipients treated with costimulation blockade will focus on al-
ternative pathways.
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